Engineered hepatitis B core virus-like particle carrier for precise and personalized Alzheimer’s disease vaccine preparation via fixed-point coupling
Source abstract
Abstract
Abstract Heterogenous aggregates of amyloid β (Aβ) and tau protein play a key role in Alzheimer’s disease (AD) progression. As the epitope profiles of Aβ and abnormally phosphorylated tau change over the course of the disease, tailor immunotherapy to specific patient groups according to the disease stage by targeting corresponding Aβ and tau species or both of tau and Aβ might improve treatment efficacy. However, epitope peptides have low immunogenicity and peptide vaccine preparation is laborious and time-consuming. We here first constructed a platform for peptide vaccine preparation by inserting SpyCatcher into the major immunodominant region (MIR) of truncated Hepatitis B core protein (HBc)(1-149). The resulted recombinant protein HBc-SpyCatcher (HBc-S) could assemble into uniform and stable virus-like particles (VLPs), and readily bind to the SpyTag conjugated epitope peptides. Several series of peptides such as linear, cyclic and phosphorylated peptides including Aβ(1-6), Aβ(1-15), cAβ(1-7), cEP1, cEP2 from β-amyloid monomer or oligomers, T294, pTau396-404, pTau422 from tau proteins, were glued onto HBc-S VLPs, forming HBc-S-peptide (HBc-S-P) VLPs and efficiently elicited specific Th2-type immune responses. When applied to AD transgenic mice, HBc-S-pTau422 alleviated cognition deficits and neuropathology progression in Tau.P301S transgenic mice. The present study provides an easy, quick, convenient and universal platform for high-throughput peptide epitope screening and personalized peptide vaccine preparation.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Biochemical and Structural Characterization · vaccines and immunoinformatics approaches · Machine Learning in Bioinformatics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease10.1016/j.neuron.2014.05.004 ↗
2. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease10.3233/JAD-2007-12410 ↗
3. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease10.1007/s004010100423 ↗
4. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments
5. Immunotherapy for Alzheimer’s disease10.1073/pnas.0404866101 ↗
6. Amsden J. QS-21 and QS-7: purified saponin adjuvants
7. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report10.1038/nm840 ↗
8. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study10.1016/S1474-4422(12)70140-0 ↗
9. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects10.1523/JNEUROSCI.0293-11.2011 ↗
10. Active Aβ immunotherapy CAD106 in Alzheimer’s disease: a phase 2b study
11. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease10.1038/s41582-018-0116-6 ↗
12. In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models10.1002/smll.201402179 ↗
13. Hollow microneedle-mediated micro-injections of a liposomal HPV E743–63 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses10.1016/j.jconrel.2017.11.035 ↗
14. Results of a phase 1/2 study in metastatic renal cell carcinoma patients treated with a patient-specific adjuvant multi-peptide vaccine after resection of metastases10.1016/j.euf.2017.09.009 ↗
15. Virus-like particles: flexible platforms for vaccine development10.1586/14760584.6.3.381 ↗
16. Bio-inspired, bioengineered and biomimetic drug delivery carriers10.1038/nrd3499 ↗
17. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes10.1097/CJI.0b013e31818f13c4 ↗
18. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns10.1038/nri2868 ↗
19. Activation of B cells by antigens on follicular dendritic cells10.1016/j.it.2010.03.002 ↗
20. Virus-like particles in vaccine development10.1586/erv.10.115 ↗
21. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies10.1177/135965350701200409 ↗
22. Virus like particles as a platform for cancer vaccine development10.7717/peerj.4053 ↗
23. Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease10.1002/eji.201445017 ↗
24. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau. P301S mouse model of Alzheimer’s disease and frontotemporal dementia10.1186/s13195-018-0378-7 ↗
25. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy10.1084/jem.20090199 ↗
26. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy10.1038/s41541-017-0030-8 ↗
27. Hepatitis B virus core particles as epitope carriers10.1159/000150415 ↗
28. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein10.1038/330381a0 ↗
29. Hepatitis B core–based virus–like particles to present heterologous epitopes10.1586/erv.12.150 ↗
30. Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo10.1016/j.biomaterials.2016.12.012 ↗
31. A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice10.1371/journal.pone.0075938 ↗
32. SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure10.1038/srep00005 ↗
33. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles10.1007/s00262-010-0895-0 ↗
34. New routes and opportunities for modular construction of particulate vaccines: stick, click and glue10.3389/fimmu.2018.01432 ↗
35. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin10.1073/pnas.1115485109 ↗
36. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide Tag10.1016/j.jmb.2013.10.021 ↗
37. Genetically encoded spy peptide fusion system to detect plasma membrane-localized proteins in vivo10.1016/j.chembiol.2015.06.020 ↗
38. A novel method for synthetic vaccine construction based on protein assembly10.1038/srep07266 ↗
39. Engineering protein hydrogels using SpyCatcher-SpyTag chemistry10.1021/acs.biomac.6b00566 ↗
40. Engineered catalytic biofilms: site-specific enzyme immobilization onto E. coli curli nanofibers10.1002/bit.25638 ↗
41. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization10.1038/srep19234 ↗
42. Combinatorial approach to hepadnavirus-like particle vaccine design10.1128/JVI.79.21.13656-13666.2005 ↗
43. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach10.2174/156720512800492503 ↗
44. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease10.1093/brain/awu213 ↗
45. Developing therapeutic vaccines against Alzheimer’s disease10.1586/14760584.2016.1121815 ↗
46. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein10.1001/archneur.63.10.1459 ↗
47. Microwave-assisted synthesis of antimicrobial peptides
48. Peptide-based synthetic vaccines10.1039/C5SC03892H ↗
49. Alzheimer’s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Abeta pathological molecules10.1038/srep28912 ↗
50. Bacterial superglue enables easy development of efficient virus-like particle based vaccines10.1186/s12951-016-0181-1 ↗